Esp8 Inhibitors
Esp8 inhibitors are a class of chemical compounds specifically designed to inhibit the activity of the Esp8 protein, which is a member of a broader family of enzymes known as serine proteases. These enzymes are characterized by their ability to cleave peptide bonds in proteins, a function essential in various biological processes, including protein degradation, signal transduction, and cellular regulation. Esp8, in particular, plays a critical role in modulating certain proteolytic pathways that are involved in cellular dynamics. The inhibitors of Esp8 are typically small molecules that bind to the active site of the enzyme, thereby blocking its catalytic activity. This inhibition is often achieved through the formation of a stable complex between the inhibitor and the enzyme, preventing the substrate from accessing the active site and being processed by the enzyme.
The design of Esp8 inhibitors often involves high-throughput screening of compound libraries to identify molecules with a high affinity for the Esp8 active site. Once identified, these molecules can be further optimized through medicinal chemistry techniques to enhance their potency, selectivity, and stability. Structural studies, such as X-ray crystallography or NMR spectroscopy, are commonly used to elucidate the binding interactions between Esp8 and its inhibitors, providing valuable insights that guide the rational design of more effective inhibitors. The chemical structures of Esp8 inhibitors are diverse, but they often contain functional groups capable of forming strong interactions, such as hydrogen bonds or hydrophobic interactions, with key residues in the enzyme's active site. By finely tuning these interactions, chemists aim to develop inhibitors that are not only potent but also highly selective for Esp8 over other related proteases, minimizing off-target effects and ensuring precise modulation of Esp8's enzymatic activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MAPK/ERK kinase, and its inhibition can potentially activate Esp8 by preventing negative regulation through ERK-mediated pathways, thereby promoting Esp8-related cellular processes. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662 is an AMP-activated protein kinase (AMPK) activator. Activation of AMPK by A769662 may influence Esp8 through AMPK-mediated signaling, contributing to Esp8 activation and modulation of downstream cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Inhibition of p38 MAP kinase may activate Esp8 by preventing negative regulation through p38 MAP kinase-dependent pathways, leading to Esp8 activation and modulation of cellular processes associated with Esp8. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 inhibits NF-κB activation. Inhibition of NF-κB may activate Esp8 by preventing its regulation through NF-κB-dependent pathways, influencing downstream cellular processes associated with Esp8, and contributing to Esp8 activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187, a calcium ionophore, may activate Esp8 by influencing calcium-dependent signaling pathways. The increase in intracellular calcium levels can modulate Esp8 activity and contribute to the regulation of Esp8-dependent cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, and its inhibition may activate Esp8 by preventing negative regulation through MEK-dependent pathways, leading to Esp8 activation and modulation of cellular processes associated with Esp8. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW501516 is a PPARδ agonist. Activation of PPARδ by GW501516 can potentially influence Esp8 through PPARδ-mediated signaling, contributing to Esp8 activation and modulation of downstream cellular processes. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 inhibits Ca2+/calmodulin-dependent protein kinase II (CaMKII). Inhibition of CaMKII may activate Esp8 by preventing its phosphorylation and modulating downstream signaling pathways. This influence on intracellular signaling cascades can contribute to Esp8 activation. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone is a PPARγ agonist. Activation of PPARγ by Rosiglitazone can potentially influence Esp8 through PPARγ-mediated signaling, contributing to Esp8 activation and modulation of downstream cellular processes. | ||||||